Hematology and Immune-Related Oncology Research

At Hospital Universitario Hermanos Trias y Pujol and the Institut Catalá d’Oncología (ICO) in Badalona, clinical research in oncology focuses on hemic and lymphatic diseases as well as immune system diseases. The studies are centered on improving treatment options for blood cancers, especially acute myeloid leukemia, while also exploring broader cancer-related care.

  • Evaluating new treatment approaches for acute myeloid leukemia to improve remission outcomes
  • Comparing different ways to use established therapies in hematologic malignancies for better effectiveness and safety
  • Supporting research in immune system diseases linked to oncology care and blood disorders

This research site is contributing to studies that aim to refine treatment strategies, strengthen response rates, and make care more effective for patients with complex blood-related cancers.

Acute Myeloid Leukemia Clinical Trials

A major part of the trial activity at this site is dedicated to acute myeloid leukemia, with studies designed to test whether modified treatment approaches can maintain strong results while potentially improving tolerability. These trials are focused on patients who are not candidates for intensive induction therapy and seek to optimize real-world treatment effectiveness.

  • Testing a new way to combine and schedule therapies for acute myeloid leukemia
  • Assessing whether shorter exposure to treatment can preserve remission outcomes
  • Improving the balance between treatment effectiveness and safety in blood cancer care

The research reflects a strong interest in finding practical, patient-friendly options for leukemia management, with a clear emphasis on response quality and clinical benefit.

Blood Cancer and Oncology Treatment Innovation

The oncology program at this health care site includes trials aimed at advancing care for hemic and lymphatic diseases. The main goal is to evaluate whether updated treatment strategies can improve outcomes for people living with difficult-to-treat blood cancers, especially acute myeloid leukemia.

  • Studying treatment effectiveness in blood cancer populations
  • Exploring better-supported options for patients with limited treatment tolerance
  • Contributing to evidence that may guide future cancer care

With multiple investigators involved, the site supports collaborative clinical research that aims to improve outcomes and inform more tailored approaches in oncology.